



BioAlliance Pharma
The Drug Resistance Company

BioAlliance Pharma announces consolidated revenues for Q1 2007

BioAlliance becomes European player

Three products now in Phase III

Paris, April 26, 2007 -- BioAlliance Pharma SA (Euronext Paris – Code Isin : FR0010095596 - BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today its revenues for Q1 2007.

In thousands of euros, excluding sales tax, IFRS compliant	2007	2006
First quarter	113	125

As in 2006, the revenues for Q1 2007 derive from services supplied by BioAlliance Pharma to Eurofins-VIRalliance (EVI, Inc.).

Q1 Highlights

- BioAlliance Pharma concluded its first joint venture agreement on March 7. The joint venture, with Spepharm, a Netherlands-based specialty pharma company, is dedicated to the setting up of a European sales and marketing organization for Loramyc®. Loramyc® was registered in France in October 2006. The European mutual recognition procedure will follow during 2007, thus allowing registration in other European countries. This has two important implications: the company is fully on target with its strategic development plan, and the agreement with Spepharm means BioAlliance has become a player in the European market. Under the terms of the agreement, BioAlliance will receive EUR 29.5M from Spepharm, of which EUR 8M in Q2 2007. This is made up of a EUR 5M capital increase subscribed to by Spepharm (approved at the company shareholders' meeting on April 24, 2007) and EUR 3M from license revenues.
- BioAlliance Pharma has obtained approval from four countries (France, Australia, Germany and the Czech Republic) to begin a Phase III clinical trial for acyclovir Lauriad® for oral herpes. It brings the number of Phase III trials being conducted by the company to three, the others being Loramyc® for oropharyngeal candidiasis to allow registration with the FDA (trial taking place in the USA, Canada and South Africa), and doxorubicin Transdrug® for primary liver cancer, which has been granted orphan status in Europe.

BioAlliance Pharma has developed a solid portfolio of products at an advanced stage of development while at the same time pursuing research programs on new entities which act in new ways in the fields of HIV and cancer.

About BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.

Specialty pharma targets the development and marketing of drugs for specialist markets and selected populations. This business model, unlike that of “big pharma” which targets general medicine, offers faster product development, lower R&D costs, smaller sales teams, and hence higher margins and fast growth.

The Company is developing three broad product ranges based on the Lauriad(R) mucoadhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.

The Loramyc(R) (miconazole Lauriad(R)) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In October 2006, the company obtained Marketing Authorization for this product in France. A pivotal Phase III trial of Loramyc(R) is ongoing in the US for the same indication. The company has submitted a Phase III protocol for a second product, acyclovir Lauriad(R), an oral herpes treatment. Approval was granted in Australia, France, Germany and the Czech Republic in February and March 2007. A Phase II/III trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology started in Europe in December 2006. This product has been granted orphan drug status by the EMEA and the FDA.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 28 April 2006 under the number R. 06-042, which is available on the AMF website <http://www.amf-france.org> or BioAlliance Pharma S.A.'s website <http://www.bioalliancepharma.com>.

BioAlliance Pharma SA

Dominique COSTANTINI
President and CEO
Tel : +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com

Nicolas FELLMANN
CFO
Tel : +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ACTUS

Agnès GILBERT
Tel : +33 1 53 67 36 33
agilbert@actus.fr

Nicole ROFFÉ
Tel : +33 1 53 67 35 74
nroffe@actus.fr

Andrew Lloyd & Associates

Gilles PETITOT
Tel : +33 1 56 54 07 07
gilles@ala.com

Juliette DOS SANTOS
Tel : +33 1 56 54 07 04
juliette@ala.com